ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Accounts Payable

The latest accounts payable for LSPRU is $10B as of March 2026. That compares with $9.6B in the prior-year period — up 6.6% year over year. Investors often review this figure alongside ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, LSPRU's accounts payable moved from $9.6B to $10B — a 6.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s operating scale or balance-sheet position.

A accounts payable figure of $10B for LSPRU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LSPRU's accounts payable ($10B), review year-over-year change from $9.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.